0.00Open0.00Pre Close0 Volume0 Open Interest3.00Strike Price0.00Turnover0.00%IV274.06%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma16.04Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Sangamo Therapeutics Stock Discussion
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Gene Editi
https://www.moomoo.com/t/news/post/43596799/BYnzVJBmba
Bought big Friday, looks like I made the right call. GLTA
No comment yet